Axenogen ivis 200

Manufactured by PerkinElmer

The AXENOGEN IVIS 200 is a high-performance in vivo imaging system designed for preclinical research. The system utilizes optical imaging technology to capture and analyze bioluminescent and fluorescent signals from small animal models. It provides researchers with the ability to non-invasively monitor biological processes and track the distribution of labeled cells or molecules within living subjects.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

IVIS 200 (61 citations)

2 protocols using axenogen ivis 200

Organ Biodistribution of CHI-PEG-PTX-Cy5

Check if the same lab product or an alternative is used in the 5 most similar protocols

The same mice used for the blood half-life study were used in this
study. Mice were euthanized 6 or 48 h after CHI-PEG-PTX-Cy5 injections.
Organs (heart, lungs, liver, spleen, kidneys, muscle and brain) were
collected and fluorescence intensities from these organs were measured by a
XENOGEN IVIS 200 imaging system (PerkinElmer Inc.). Imaging parameters were
set to: excitation wavelength: 675 nm; emission filter: 720–750 nm;
exposure time: 1 second; binning factor: 2; f/stop: 4.

Mu Q., Lin G., Stephen Z.R., Chung S., Wang H., Patton V.K., Gebhart R.N, & Zhang M. (2020). In vivo Serum Enabled Production of Ultrafine Nanotherapeutics for Cancer Treatment. Materials today (Kidlington, England), 38, 10-23.

+ Open protocol

+ Expand

Preclinical Evaluation of Compound 74

Check if the same lab product or an alternative is used in the 5 most similar protocols

Female
athymic CrTac:NCr-Foxn1^nu mice from Taconic (6–8 weeks of age) were injected subcutaneously
in the flank with 3 million COLO205-F1756 clone 4 cells, and when
tumor xenografts reached a mean diameter of 5–6 mm (equating
to a mean volume of about 100 mm³), mice (n = 8 per group) were dosed orally by gavage with compound 74 (70 mg/kg bid for 8 days) or vehicle (10% dimethyl sulfoxide; 5%
Tween 20 in sterile saline). Luminescent flux as a measure of WNT
pathway activity was quantified by whole body imaging in cohorts of
four animals at 2 and 6 h after the final dose. This was achieved
by sc injection of 100 μL of 30 mg/mL D-Luciferin firefly substrate
(XR-1001, PerkinElmer) into anaesthetized mice and imaging with a
Xenogen IVIS 200 (XR-1001, PerkinElmer), utilizing the software Living
Image (version 4). At these time points, heparinized blood samples
were collected by cardiac puncture under terminal anesthesia, and
plasma was separated by centrifugation. Tumors were excised and weighed,
and both plasma and tumor samples were snap frozen for PK analyses.

Mallinger A., Crumpler S., Pichowicz M., Waalboer D., Stubbs M., Adeniji-Popoola O., Wood B., Smith E., Thai C., Henley A.T., Georgi K., Court W., Hobbs S., Box G., Ortiz-Ruiz M.J., Valenti M., De Haven Brandon A., TePoele R., Leuthner B., Workman P., Aherne W., Poeschke O., Dale T., Wienke D., Esdar C., Rohdich F., Raynaud F., Clarke P.A., Eccles S.A., Stieber F., Schiemann K, & Blagg J. (2015). Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen. Journal of Medicinal Chemistry, 58(4), 1717-1735.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!